Hopp til hovedinnhold
Det dominerende problemet ved overaktiv blære er sterk vannlatingstrang og behov for hyppig vannlating.
Det dominerende problemet ved overaktiv blære er sterk vannlatingstrang og behov for hyppig vannlating.

Overaktiv blære

En overaktiv urinblære er karakterisert ved brått innsettende og sterk vannlatingstrang, med eller uten samtidig urinlekkasje, og hyppig vannlating og behov for å tisse om natten.

Sist oppdatert: Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/nyrerurinveier/andre-urinveissykdommer/overaktiv-blare/ 

Overaktiv blære

Årsak

Symptomer

Diagnostikk

Behandling

Egenbehandling

Medikamentell behandling

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Overaktiv blære. Referanselisten for dette dokumentet vises nedenfor.

  1. Hunskår S. Behandling av overaktiv blære-syndrom. Tidsskr Nor Lægeforen 2005; 125: 2029-30. PubMed 
  2. Abrams P, Cardozo L, Khoury S et al, red. Incontinence. 5rd International Consultation on Incontinence. 5 utg. Plymouth: Health Publication, 2013.
  3. European Association of Urology. Non-Oncology Guidelines. Nettside besøkt 23.01.2018. uroweb.org 
  4. Norsk urologisk forenings anbefalinger for allmennleger. Overaktiv urinblære. Versjon mai 2018. Siden lest 26.02.2021. www.legeforeningen.no 
  5. Lavelle JP, Karram M. Overactive bladder. Am J Med 2006; 19(3 Suppl 1): 1-2.
  6. Lavelle JP, Karram M, Chu FM, et al. Management of incontinence for family practice physicians. Am J Med 2006; 19(3 Suppl 1): 37-40.
  7. Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med 2006; 119(3 Suppl 1): 3-8.
  8. Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med 2006; 119(3 Suppl 1): 29-36.
  9. Clemens JQ. Management of interstitial cystitis/bladder pain syndrome. UpToDate, last updated May 06, 2015. UpToDate 
  10. Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014 ;46(1):275-84. doi: 10.1007/s11255-013-0509-9. DOI 
  11. Yeowell G, Smith P, Nazir J, et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018. PMID: 30467131 PubMed 
  12. Kelleher C, Hakimi Z, Zur R et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol. 2018 Sep;74(3):324-333. Epub 2018 Apr 23. PMID: 29699858. PubMed 
  13. Nabi G, Cody JD, Ellis G, Hay-Smith J, Herbison GP. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003781. DOI: 10.1002/14651858.CD003781.pub2. DOI 
  14. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non‐drug active therapies for non‐neurogenic overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD003193. DOI: 10.1002/14651858.CD003193.pub4. Accessed 22 February 2021. The Cochrane Library 
  15. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay‐Smith EJC. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD005429. DOI: 10.1002/14651858.CD005429.pub2. Accessed 26 February 2021. The Cochrane Library 
  16. Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013 Feb; 61(2): 185-93. PubMed 
  17. Abrams P, Cardozo L, Khoury S et al, red. Incontinence. 3rd International Consultation on Incontinence. 3 utg. Plymouth: Health Publication, 2005.
  18. Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non‐implanted electrodes for overactive bladder in adults. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD010098. DOI: 10.1002/14651858.CD010098.pub4. Accessed 26 February 2021. The Cochrane Library 
  19. White N, Iglesia CB. Overactive Bladder. Obstet Gynecol Clin North Am. 2016 Mar;43(1):59-68. PMID: 26880508 PubMed 
  20. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493.pub3. Accessed 26 February 2021. The Cochrane Library 
  21. Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin North Am 2006; 33: 491-501. PubMed 
  22. Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014 ;65(4):755-65. PMID: 24275310 PubMed 
  23. Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial. Eur Urol. 2019 Feb;75(2):274-282. PMID: 30661513 PubMed